Research Article| Volume 74, ISSUE 1, P37-43, January 2013

Effect of diabetes on endometrial cancer recurrence and survival



      The purpose of this study was to investigate the influence of diabetes mellitus (DM) on cancer stage at diagnosis, cancer recurrence, and survival of endometrial cancer (EC) patients and the influence of the treatment of EC on glycaemic control, treatment, and complications of DM.


      In this retrospective cohort study all 1644 patients with EC newly diagnosed in 2000–2008 and recorded in the population-based Eindhoven Cancer Registry (ECR) were included. In addition, from this total cohort a subcohort was selected for additional data collection and analyses, including 193 EC patients with DM and an age-matched sample of 195 EC patients without DM. Patients with FIGO stage IV as well as non-endometrioid histology were excluded.


      In the total cohort EC patients with DM had a significantly higher age (69 years vs. 64 years), higher FIGO stages and more additional comorbidities compared to EC patients without DM. The 5-year overall survival rate for EC patients with DM was significantly lower than for EC patients without DM (68% vs. 84%). After adjusting for age, stage, period of diagnosis, cardiovascular disease, and treatment, this significant effect of DM on overall mortality persisted (HR 1.4, 95% CI: 1.0–1.8). Subcohort analyses showed that EC patients with DM were diagnosed more often with a higher body mass index (BMI) (34 kg/m2 vs. 30 kg/m2) and EC was not significantly associated with changes in DM characteristics over time. Although the 5-year overall survival rate for EC patients with DM was significantly lower in the subcohort, for EC-specific mortality (n = 388) no statistically significant effect of DM was observed after adjustment for FIGO stage (HR = 1.7, 95% CI: 0.7–3.9).


      EC patients with DM compared to those without had worse patient characteristics, a higher FIGO stage, similar recurrence rates and worse overall survival.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fader A.N.
        • Arriba L.N.
        • Frasure H.E.
        • von Gruenigen V.E.
        Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship.
        Gynecologic Oncology. 2009; 114: 121-127
        • Friberg E.
        • Orsini N.
        • Mantzoros C.S.
        • Wolk A.
        Diabetes mellitus and risk of endometrial cancer: a meta-analysis.
        Diabetologia. 2007; 50: 1365-1374
        • Giovannucci E.
        • Harlan D.M.
        • Archer M.C.
        • et al.
        Diabetes and cancer: a consensus report.
        CA: A Cancer Journal for Clinicians. 2010; 60: 207-221
        • Lindemann K.
        • Vatten L.J.
        • Ellstrom-Engh M.
        • Eskild A.
        Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study.
        British Journal of Cancer. 2008; 98: 1582-1585
        • Wedisinghe L.
        • Perera M.
        Diabetes and the menopause.
        Maturitas. 2009; 63: 200-203
        • Bray F.
        • Dos Santos Silva I.
        • Moller H.
        • Weiderpass E.
        Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention.
        Cancer Epidemiology, Biomarkers and Prevention. 2005; 14: 1132-1142
        • Sloan F.A.
        • Bethel M.A.
        • Ruiz D.
        • Shea A.M.
        • Feinglos M.N.
        The growing burden of diabetes mellitus in the US elderly population.
        Archives of Internal Medicine. 2008; 168 (discussion 199): 192-199
        • Cancer in the Netherlands till 2020
        Trends and prognoses.
        Signalling Committee Cancer of the Dutch Cancer Society, Amsterdam2011 (ISBN: 90-71229-00-8)
      1. Baan CA, Schoemaker CG, Jacobs-van der Bruggen MAM, et al. Diabetes tot 2025; preventie en zorg in samenhang. RIVM-rapport 260322004; 2009.

        • Cancer in the Netherlands
        Trends, prognoses and implications for healthcare.
        90-71229-13-0 Signalling Committee Cancer of the Dutch Cancer Society, Amsterdam2004
        • Barone B.B.
        • Yeh H.C.
        • Snyder C.F.
        • et al.
        Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.
        JAMA. 2008; 300: 2754-2764
        • Chia V.M.
        • Newcomb P.A.
        • Trentham-Dietz A.
        • Hampton J.M.
        Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis.
        International Journal of Gynecological Cancer. 2007; 17: 441-446
        • Folsom A.R.
        • Anderson K.E.
        • Sweeney C.
        • Jacobs Jr., D.R.
        Diabetes as a risk factor for death following endometrial cancer.
        Gynecologic Oncology. 2004; 94: 740-745
        • Steiner E.
        • Eicher O.
        • Sagemuller J.
        • et al.
        Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University.
        International Journal of Gynecological Cancer. 2003; 13: 197-203
        • van de Poll-Franse L.V.
        • Houterman S.
        • Janssen-Heijnen M.L.
        • Dercksen M.W.
        • Coebergh J.W.
        • Haak H.R.
        Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis.
        International Journal of Cancer. 2007; 120: 1986-1992
        • Boll D.
        • Verhoeven R.H.
        • van der Aa M.A.
        • Lybeert M.L.
        • Coebergh J.W.
        • Janssen-Heijnen M.L.
        Adherence to national guidelines for treatment and outcome of endometrial cancer stage I in relation to co-morbidity in southern Netherlands 1995–2008.
        European Journal of Cancer. 2011; 47: 1504-1510
        • Johnson J.A.
        • Carstensen B.
        • Witte D.
        • Bowker S.L.
        • Lipscombe L.
        • Renehan A.G.
        Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence.
        Diabetologia. 2012; 55: 1607-1618
        • Renehan A.G.
        • Yeh H.C.
        • Johnson J.A.
        • Wild S.H.
        • Gale E.A.
        • Moller H.
        Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.
        Diabetologia. 2012; 55: 1619-1632
        • Zuurendonk L.D.
        • Smit R.A.
        • Mol B.W.
        • et al.
        Routine pelvic lymphadenectomy in apparently early stage endometrial cancer.
        European Journal of Surgical Oncology. 2006; 32: 450-454
      2. National Dutch guideline of endometrial cancer; 2011.

        • Creutzberg C.L.
        • van Putten W.L.
        • Koper P.C.
        • et al.
        Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial, PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
        Lancet. 2000; 355: 1404-1411
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        Journal of Chronic Diseases. 1987; 40: 373-383
      3. International classification of diseases of oncology. Version 2007.
        1st ed. WHO, Geneva1976
        • van Duijn C.
        • Keij I.
        Sociaal-economische status indicator op postcode niveau.
        Maandstatistiek van de bevolking. 2002; 50: 32-35
        • Bokhman J.V.
        Two pathogenetic types of endometrial carcinoma.
        Gynecologic Oncology. 1983; 15: 10-17
        • Creasman W.T.
        • Odicino F.
        • Maisonneuve P.
        • et al.
        Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer.
        International Journal of Gynecology and Obstetrics. 2006; 95: S105-S143
        • Boll D.
        • Hermans R.H.M.
        • Keijser K.G.G.
        • et al.
        Bundeling Regionale Expertise Gynaecologische Oncologie.
        Medisch Contact. 2009; 64: 942-945
        • van Herk-Sukel M.P.
        • van de Poll-Franse L.V.
        • Lemmens V.E.
        • et al.
        New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System.
        European Journal of Cancer. 2010; 46: 395-404
        • Kurman R.J.
        • Ellenson L.H.
        • Ronnett B.M.
        Blaustein's pathology of the female genital tract.
        6th ed. Springer-Verlag, New York, NY2011
        • Moon H.S.
        • Chamberland J.P.
        • Aronis K.
        • Tseleni-Balafouta S.
        • Mantzoros C.S.
        Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans.
        Molecular Cancer Therapeutics. 2011; 10: 2234-2243
        • Cust A.E.
        • Kaaks R.
        • Friedenreich C.
        • et al.
        Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women.
        Journal of Clinical Endocrinology and Metabolism. 2007; 92: 255-263
        • Vigneri P.
        • Frasca F.
        • Sciacca L.
        • Pandini G.
        • Vigneri R.
        Diabetes and cancer.
        Endocrine-Related Cancer. 2009; 16: 1103-1123
        • Cantrell L.A.
        • Zhou C.
        • Mendivil A.
        • Malloy K.M.
        • Gehrig P.A.
        • Bae-Jump V.L.
        Metformin is a potent inhibitor of endometrial cancer cell proliferation – implications for a novel treatment strategy.
        Gynecologic Oncology. 2010; 116: 92-98
        • Olson S.H.
        • Atoria C.L.
        • Cote M.L.
        • et al.
        The impact of race and comorbidity on survival in endometrial cancer.
        Cancer Epidemiology, Biomarkers and Prevention. 2012; 21: 753-760
        • Demark-Wahnefried W.
        • Campbell K.L.
        • Hayes S.C.
        Weight management and its role in breast cancer rehabilitation.
        Cancer. 2012; 118: 2277-2287
        • Janssen-Heijnen M.L.
        • Houterman S.
        • Lemmens V.E.
        • Louwman M.W.
        • Maas H.A.
        • Coebergh J.W.
        Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach.
        Critical Reviews in Oncology/Hematology. 2005; 55: 231-240